Conatumumab
Conatumumab (pronounced as koh-NAT-uh-muh-bab) is a type of monoclonal antibody that is being studied in the treatment of certain types of cancer. It is a type of apoptosis inducer and a type of immunotoxin.
Etymology
The term "Conatumumab" is derived from Latin, where "conatus" means effort or endeavor, and "mab" is an abbreviation for monoclonal antibody. The name reflects the drug's function as a targeted effort against cancer cells.
Usage
Conatumumab is used in the treatment of various types of cancer, including colorectal cancer, pancreatic cancer, and non-small cell lung cancer. It works by binding to a protein called TRAIL-R2 (also known as Death Receptor 5), which is found on the surface of many cancer cells. This binding triggers a process called apoptosis, or programmed cell death, in the cancer cells.
Related Terms
- Monoclonal antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells.
- Apoptosis: A type of cell death in which a series of molecular steps in a cell lead to its death. This is one method the body uses to get rid of unneeded or abnormal cells.
- Immunotoxin: A substance that has an antibody to target specific cells and a toxin to kill them.
- TRAIL-R2: A protein on the surface of cells that can trigger apoptosis when activated.
See Also
External links
- Medical encyclopedia article on Conatumumab
- Wikipedia's article - Conatumumab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski